NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Hepta Bio

Hepta Bio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://www.hepta.bio/

Last Round

Seed

Nov 5, 2025

Total Funding Raised

$6.7M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Hepta Bio is a biotechnology company that develops a liquid biopsy and AI platform to read the cell-free DNA epigenome and detect organ-specific signals of chronic disease, with an initial focus on metabolic dysfunction-associated steatohepatitis (MASH).

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical AI, Precision Medicine, Healthcare Analytics, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service, Government Contracts

AI Layer

Application

Keywords

liquid biopsynon-invasive diagnosticsMASHepigenomicscell-free DNAcfDNAAI diagnosticsliver biopsy alternativechronic disease detectionliver disease detectionprecision medicinemolecular diagnosticsMetabolic Dysfunction-Associated Steatohepatitisclinical trial diagnostics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Hepta Bio Comparables

Compare Hepta Bio with similar companies based on industry and business-model similarity.

Hepta Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AGED Diagnostics
89%
Glycotest, Inc.
75%
EarlyDiagnostics
71%

Hepta Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedNov 5, 2025

Key People

Founding team and executive leadership

Soheil Damangir

Co-Founder And CTO

Founding Team

Hamed Amini

Co-founder CEO

Founding Team

Hepta Bio Investors

Notable investors and investment history

Hepta Bio investors
InvestorRounds
SeaX VenturesSeed
AME Cloud VenturesSeed
Alumni VenturesSeed
Felicis VenturesSeed
Illumina VenturesSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 24, 2026

    Grew 100% QoQ from 3 to 6 employees.

  • Apr 19, 2026

    Monthly visitors increased 35% MoM, reaching 2.8K.

Hepta Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Hepta Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Hepta Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range6
Year Founded2021
Last FundingNov 5, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.